AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Autolus Therapeutics plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.59−0.01 (-0.63%)
Close on Oct 19, 2026
- Market cap
- $423.19M
- P/E (TTM)
- –
- Dividend yield
- –
Autolus Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Autolus Therapeutics | Industry median |
|---|---|---|
| Market Cap | $423.20M | $164.85M |
| Enterprise Value | $221.57M | $87.06M |
| PS Ratio | 3.61 | 3.60 |
| PB Ratio | 5.65 | 2.03 |
| P/TBV Ratio | 7.52 | 2.31 |
Enterprise value
| Measure | Autolus Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 1.89 | 2.43 |
Income (trailing twelve months)
| Measure | Autolus Therapeutics | Industry median |
|---|---|---|
| Revenue | $117.39M | $57.94M |
| Gross Profit | $18.38M | $90.47M |
| Operating Income | -$247.44M | -$21.44M |
| Pretax Income | -$279.48M | -$14.45M |
| Net Income | -$280.16M | -$22.46M |
| EBITDA | -$238.85M | -$16.91M |
| EPS (Diluted) | -$1.06 | -$0.83 |
Margins
| Measure | Autolus Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 15.7% | 52.3% |
| Operating Margin | -210.8% | -44.5% |
| Pretax Margin | -238.1% | -13.0% |
| Profit Margin | -238.7% | -39.2% |
| EBITDA Margin | -203.5% | -31.3% |
| FCF Margin | -198.3% | -8.85% |
Returns
| Measure | Autolus Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -133.0% | -53.1% |
| Return on Assets (ROA) | -46.1% | -41.0% |
| Return on Capital Employed (ROCE) | -58.3% | -37.8% |
Growth
| Measure | Autolus Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 292.2% | 6.01% |
Balance sheet
| Measure | Autolus Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $201.63M | $62.42M |
| Net Cash (Debt) | $201.63M | $15.68M |
| Net Cash Per Share | $0.76 | $0.66 |
| Equity (Book Value) | $74.84M | $48.79M |
| Book Value Per Share | $0.28 | $1.36 |
| Tangible Book Value | $56.31M | $23.06M |
| Working Capital | $267.30M | $75.77M |
Financial position
| Measure | Autolus Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.89 | 3.30 |
| Quick Ratio | 3.58 | 2.39 |
| Interest Coverage | -5.92 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Autolus Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$225.61M | -$12.35M |
| Capital Expenditures | -$7.12M | -$1.06M |
| Free Cash Flow | -$232.73M | -$20.28M |
| FCF Per Share | -$0.87 | -$0.42 |
Efficiency
| Measure | Autolus Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.19 | 0.38 |
| Inventory Turnover | 3.45 | 2.67 |
| Revenue Per Employee | $155.69K | $398.96K |
| Profits Per Employee | -$371.56K | -$703.34K |
| Employee Count | 754 | 74 |
Dividends and yields
| Measure | Autolus Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -66.2% | -22.7% |
| FCF Yield | -55.0% | -9.07% |
Shares
| Measure | Autolus Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 266,163,000 | 58,179,650 |
| Shares Change (YoY) | 0.00% | 11.1% |
| Float | 221,133,000 | 49,173,100 |
| Shares Held by Insiders | 16.9% | 11.6% |
| Shares Held by Institutions | 49.7% | 59.4% |
Taxes
| Measure | Autolus Therapeutics | Industry median |
|---|---|---|
| Income Tax | $677.00K | $91.50K |
Scores
| Measure | Autolus Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -4.41 | -0.24 |
| Piotroski F-Score | 2 | 4 |
| Beneish M-Score | 200.05 | -2.62 |
Calculated by StockData from Autolus Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.